无血性
重性抑郁障碍
药品
医学
系数H
心理学
毒品天真
补语(音乐)
补体系统
药理学
心情
免疫学
精神科
免疫系统
精神分裂症(面向对象编程)
生物
表型
生物化学
互补
基因
作者
Wei Tang,Hongyang Liu,Lixian Chen,Ke Zhao,Yaoyao Zhang,Ke Zheng,Cheng Zhu,Tiansheng Zheng,Jiahong Liu,Dandan Wang,Lingfang Yu,Xinyu Fang,Chen Zhang,Kuan‐Pin Su
标识
DOI:10.1016/j.bbi.2021.03.022
摘要
Anhedonia is a core symptom of major depressive disorder (MDD) and often associated with poor prognosis. The main objective of the present study was to explore the relationship between complement factor H (CFH), inflammatory cytokines and anhedonia in drug-naïve MDD patients.A total of 215 participants (61 MDD patients with anhedonia, 78 MDD patients without anhedonia, and 76 control subjects) were included. Severity of depression and levels of anhedonia were evaluated by Hamilton Rating Scale for Depression-17 (HAMD-17) and SHAPS (Snaith-Hamilton Pleasure Scale). Plasma levels of CFH, interleukin-6 (IL-6), IL-10 and tumor necrosis factor-α (TNF-α) were measured.The plasma levels of CFH, IL-10 and TNF-α were higher in drug-naïve MDD patients than control subjects. Compared to MDD patients without anhedonia, patients with anhedonia showed higher levels of CFH and IL-6. The stepwise regression analysis revealed that IL-10, TNF-α, as well as IL-10 × TNF-α were associated with depressive symptoms measured by HAMD-17 in drug-naïve MDD patients, while only CFH levels were identified as a mediator factor for the severity of anhedonia in the patients.MDD patients with anhedonia showed different inflammatory characteristics compared to patients without anhedonia. Our results provide novel evidence suggesting that increased plasma CFH levels may be a potential biomarker of anhedonia of subtyping MDD.
科研通智能强力驱动
Strongly Powered by AbleSci AI